Company: NCEL
Filing Date: 2025-09-25
Form Type: F-1
Source: 0001213900-25-091697
Chunk: 31

Company: NewcelX Ltd.
Filing Date: 2025-09-25
Form: F-1
Chunk 31
---
 for example due to the failure to obtain shareholder approval; |

| ● | the occurrence of any event, change or other circumstances       
 that could give rise to the termination of the Merger Agreement; |

| ● | the expected benefits of the Merger; |

| ● | the unexpected costs related to the proposed Merger; |

| ● | the financial and business performance of NLS, including                              
 financial projections and business metrics and any underlying assumptions thereunder; |

| ● | changes in NLS’s and Kadimastem’s strategy, future                                                   
 operations, financial position, estimated revenues and losses, projected costs, prospects and plans; |

| ● | the implementation, market acceptance and success of NLS’s 
 and Kadimastem’s business model;                           |

| ● | NLS’s and Kadimastem’s ability to scale in a 
 cost-effective manner;                       |

| ● | developments and projections relating to NLS’s and 
 Kadimastem’s competitors and industry;             |

| ● | NLS’s and Kadimastem’s expectations regarding                                                                 
 its ability to obtain and maintain intellectual property protection and not infringe on the rights of others; |

| ● | expectations regarding the time during which NLS will be                  
 an emerging growth company under the Jumpstart Our Business Startups Act; |

| ● | NLS’s and Kadimastem’s future capital requirements 
 and sources and uses of cash;                      |

| ● | NLS’s and Kadimastem’s ability to obtain funding 
 for their operations;                            |

| ● | NLS’s and Kadimastem’s business, expansion plans 
 and opportunities;                               |

<div align='center'>15</div>

| ● | NLS’s and Kadimastem’s management and board of 
 directors;                                     |

| ● | the listing of NLS’s securities on Nasdaq; |

| ● | geopolitical risk and changes in applicable laws or regulations; |

| ● | fluctuations in exchange rates between the foreign currencies                       
 in which NLS and Kadimastem typically do business and the United States dollar; and |

| ● | the outcome of any known and unknown litigation and regulatory 
 proceedings.                                                   |

Those factors are also discussed in the section “Risk Factors” beginning on page 13 of this prospectus.

These
statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our
or our industry’s actual results, levels of activity, performance or achievements to be